• Subjects were required to have heterozygous familial hypercholesterolemia, established CAD, or coronary heart disease risk equivalent
  • Average baseline LDL was 122 mg/dl
  • All patients also took maximally-tolerated statins
  • Reference [2]
Alirocumab vs placebo for 24 weeks in patients at high-risk for cardiovascular disease
Lipid parameter Alirocumab 150 mg every 2 weeks
(N=1530)
Placebo
(N=780)
LDL
(% change from baseline)
-61% 0.8%
Total
(% change from baseline)
-38% -0.3%
HDL
(% change from baseline)
4.0% -0.6%
Triglycerides
(% change from baseline)
-15.6% 1.8%


  • Subjects had CVD and were stabilized on atorvastatin 80 mg, rosuvastatin 40 mg, or simvastatin 40 mg
  • Average baseline LDL was 108 mg/dl
  • Non-HDL-C = total cholesterol - HDL
  • Reference [3]
Evolocumab (Evo) vs placebo for 12 weeks in patients with CVD taking statins
Lipid parameter Evo 140 mg every 2 weeks
(N=105)
Evo 420 mg once monthly
(N=105)
Placebo
(N=86)
LDL
(% change from baseline)
-64% -58% +6%
Total
(% change from baseline)
-38% -32% +3%
Non-HDL-C
(% change from baseline)
-56% -47% +3%
Apo B
(% change from baseline)
-49% -46% +4%